Product Overview
Dragon Pharma Oral Tren contains methyltrienolone, also written metribolone, in tablets of 250 micrograms. That unit is the first thing to notice: this is not a milligram product, and a single tablet is a quarter of one milligram. Methyltrienolone is a 17-alpha-methylated derivative related to trenbolone by structure, orally active, and regarded in the reference material as one of the most aggressive oral agents available.
Its profile splits in two directions. The anabolic signal is strong, which is why the compound is described as producing a sharp jump in strength within days, and it does not convert to estradiol, so water and estrogen-driven swelling are not part of the picture. Against that, it is heavily hepatotoxic, carries progestogenic activity, and is documented as causing general malaise early even at low intake. Community practice treats it as a niche tool for experienced users who accept a very short window and who monitor liver values closely, and the sources describe it as comparable in liver load to other 17-alpha orals while acting more strongly.
The injectable forms live in the same catalogue, from Trenbolone 100 to Parabolan 100, and the oral route does not make those esters gentle - it simply adds first-pass liver exposure to a compound that is already harsh there.
Dosage Protocol
Doses are written in micrograms and the daily total is divided, because the activity window is short. The figures below are the reference range that appears in the sources, and anything above them is linked there to side effects rather than to extra results.
| Beginner | 250 mcg a day for two weeks; more than this is linked to rising liver enzymes and rapid loss of well-being |
| Intermediate | 250-500 mcg a day for two to three weeks, split across the day because activity is short |
| Advanced | Up to 500 mcg a day, rarely more, with a three to four week ceiling |
| Female | Not recommended; the androgenic load and the hepatic risk are both extreme and no female protocols exist in the sources |
| Administration | Oral, divided through the day; the tablet is 250 mcg, and the metered dose is the reason a pill cutter is useless here |
The reason for the sub-milligram scale is not marketing: the compound is described as out-acting other 17-alpha orals at a fraction of the quantity, and the safety margin is correspondingly thin. Anyone who treats a 250 mcg tablet as if it were 25 mg has skipped the only part of this page that matters. Liver support such as TUDCA or NAC appears in the sources as a companion measure, not as permission to extend the cycle.
Suggested Protocols
The compound is used as an addition to a stack rather than as a base, and the length is deliberately short. Both of the layouts below assume liver support is already in place.
What to Expect
- Strength, fast. A sharp rise in force output is usually reported within the first days, and it is the reason the compound is used at all.
- Hardness without water. By week one or two the muscle looks denser; there is no aromatisation, so no subcutaneous water follows.
- Almost no scale movement. Bodyweight gain is minimal, which is a property of the molecule and not a sign the product is weak.
- Early warning signs. Poor appetite and a general feeling of being unwell are described as the first signals of intolerance, and they appear in the literature even on low intake.
- Liver values climb quickly. Enzyme rises are rapid rather than gradual, so bloodwork during the block is the only reliable check.
- Progestogenic activity. Because the molecule does not aromatise, chest problems arrive through a different route, which is why the usual aromatase inhibitor logic does not cover them.
- Limitation: no confirmed timing numbers. With no established half-life and no published detection figure, intake schedules follow practice rather than a verified value.
Side Effects and Management
This is the section that decides whether the product is suitable for a given person. The compound is not a candidate for casual use, and the honest summary of the reference material is that the risks arrive early and are dose-dependent.
One clarification worth stating plainly: an aromatase inhibitor such as Aromasin has no route to correct a progestogenic effect, because the molecule never converts to estradiol in the first place. Using one as a precaution here adds side effects without addressing the mechanism.
Post-Cycle Therapy
The oral form clears its activity within days, so recovery starts soon after the last tablet. Suppression is still severe, which is why the protocol is not shortened.
